Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.

Blood
Paolo GallipoliBrian J P Huntly

Abstract

FLT3 internal tandem duplication (FLT3ITD) mutations are common in acute myeloid leukemia (AML) associated with poor patient prognosis. Although new-generation FLT3 tyrosine kinase inhibitors (TKI) have shown promising results, the outcome of FLT3ITD AML patients remains poor and demands the identification of novel, specific, and validated therapeutic targets for this highly aggressive AML subtype. Utilizing an unbiased genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 screen, we identify GLS, the first enzyme in glutamine metabolism, as synthetically lethal with FLT3-TKI treatment. Using complementary metabolomic and gene-expression analysis, we demonstrate that glutamine metabolism, through its ability to support both mitochondrial function and cellular redox metabolism, becomes a metabolic dependency of FLT3ITD AML, specifically unmasked by FLT3-TKI treatment. We extend these findings to AML subtypes driven by other tyrosine kinase (TK) activating mutations and validate the role of GLS as a clinically actionable therapeutic target in both primary AML and in vivo models. Our work highlights the role of metabolic adaptations as a resistance mechanism to several TKI and suggests glutaminolysis ...Continue Reading

References

Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Jun 3, 2004·Cancer Research·Rebecca L ElstromCraig B Thompson
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Nov 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Ralph J DeBerardinisCraig B Thompson
Mar 14, 2008·Nature·Heather R ChristofkLewis C Cantley
Apr 9, 2008·Oncogene·D N GrossM J Birnbaum
Nov 27, 2008·Proceedings of the National Academy of Sciences of the United States of America·David R WiseCraig B Thompson
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 17, 2013·BMC Bioinformatics·Edward Y ChenAvi Ma'ayan
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Feb 14, 2014·Molecular Cancer Therapeutics·Matt I GrossMark K Bennett
Jun 3, 2014·Therapeutic Advances in Hematology·Seth A WanderAmir T Fathi
Dec 31, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesca Alvarez-CalderonJames DeGregori
Mar 24, 2015·The Journal of Clinical Investigation·Kazuhiro TanakaEiji Kohmura
May 5, 2016·Nucleic Acids Research·Maxim V KuleshovAvi Ma'ayan
Jun 22, 2016·Archivum Immunologiae Et Therapiae Experimentalis·Barbara ZdzisińskaMartyna Kandefer-Szerszeń
Sep 1, 2016·The New England Journal of Medicine·François LemonnierTak W Mak
Oct 30, 2016·Proceedings of the National Academy of Sciences of the United States of America·Mark A GregoryJames DeGregori
Feb 17, 2017·The Journal of Experimental Medicine·Amelie V GuitartKamil R Kranc

❮ Previous
Next ❯

Citations

May 9, 2019·Physiological Reviews·Julhash U Kazi, Lars Rönnstrand
Nov 16, 2019·Angewandte Chemie·Islam AlshamlehHarald Schwalbe
Aug 3, 2019·Cells·Johanna KreitzHubert Serve
Dec 4, 2019·Acta Pharmacologica Sinica·Hui Xing, Ling-Hua Meng
Apr 14, 2018·Blood·Samuel J Taylor, Ulrich Steidl
Oct 18, 2018·American Journal of Hematology·Elihu H Estey
Oct 16, 2018·Frontiers in Cell and Developmental Biology·Angela IannicielloG Vignir Helgason
Aug 21, 2020·Nucleic Acids Research·Jingwen WangVicent Pelechano
Apr 2, 2018·International Journal of Hematology·Adam C Wilkinson, Satoshi Yamazaki
Jul 20, 2019·BMC Biology·Lucille StuaniJean-Emmanuel Sarry
Sep 4, 2020·World Journal of Clinical Oncology·Lindsay WildeMargaret Kasner
Mar 21, 2019·The Journal of Experimental Medicine·Faisal BasheerBrian J P Huntly
Apr 1, 2019·Cancer Reports·Travis NemkovJulie A Reisz
Nov 5, 2019·Genes & Development·Marissa Rashkovan, Adolfo Ferrando
May 13, 2020·Cells·Ida Sofie GrønningsæterKimberley Joanne Hatfield
Mar 21, 2020·Signal Transduction and Targeted Therapy·Dan LiJianfeng Zhou
Oct 3, 2020·Cancers·Jörg P Müller, Dirk Schmidt-Arras
Apr 4, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark A GregoryJames DeGregori
Mar 25, 2021·The Journal of Experimental Medicine·Lucille StuaniJean-Emmanuel Sarry
Apr 23, 2021·Cancer & Metabolism·Svetlana B PaninaNatalia V Kirienko
Jan 14, 2021·Cancer Discovery·Stefan BjelosevicRicky W Johnstone
May 23, 2021·Trends in Cancer·Wen-Hsuan YangMichael J Lukey
May 25, 2021·Blood Cancer Discovery·Dongqing YanMichael W Deininger
Jun 8, 2021·Frontiers in Oncology·Vilma Dembitz, Paolo Gallipoli
Jun 8, 2021·Frontiers in Oncology·Livingstone FultangFrancis J Mussai
Dec 24, 2020·Blood Reviews·Binyan XuYuhua Li
Jul 8, 2021·Cancer Discovery·Dongqing YanMichael W Deininger
Jul 30, 2021·DNA Repair·Ujjayinee Ray, Sathees C Raghavan
Aug 28, 2021·International Journal of Molecular Sciences·Ioanna E Stergiou, Efstathia K Kapsogeorgou
Aug 28, 2021·International Journal of Molecular Sciences·Ludovica Di MartinoErich Piovan
Sep 26, 2021·Leukemia·Lucie de BeauchampG Vignir Helgason

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.